Costs of Cancer Care for Elderly Patients with Neuroendocrine Tumors

Chan Shen, Arvind Dasari, Dian Gu, Yiyi Chu, Shouhao Zhou, Ying Xu, Daniel Halperin, Shuangshuang Fu, James C. Yao, Ya Chen Tina Shih

Research output: Contribution to journalArticle

Abstract

Background: The incidence and prevalence of neuroendocrine tumors (NETs) have been steadily rising. NETs can arise in various parts of the body and have distinct pathogenesis, clinical manifestations, treatment, and survival compared to other neoplasms. The magnitude of the economic burden of NETs is largely unknown. This study aimed to estimate the cost of illness for NETs among elderly patients based on a large amount of observational data. Methods: We estimated the direct medical costs by phase of care using the Surveillance, Epidemiology, and End Results-Medicare data, including claims from January 1, 2002 through to December 31, 2012. Patients’ care was categorized into three phases: initial phase (first year after diagnosis), terminal phase (last year of life), and continuing phase (the period between). We estimated the cost of illness by calculating the difference in medical costs between NET patients and a matched sample from a non-cancer control group. Results: Our study sample included 8409 elderly NET patients in the initial phase, 9218 patients in the continuing phase, and 7897 in the terminal phase. The mean cost of care for the initial phase was $46,462 in 2016 US dollars; mean cost of care for the terminal phase with a cancer-related death was $122,702; while the mean cost of care for the continuing phase was $10,457. The mean 5-year cost was $87,079. Conclusions: This population-based study showed that NET patients had substantial continuing phase costs and 5-year costs. Among elderly NET patients, those with pancreas as the primary cancer site had the highest costs.

Original languageEnglish (US)
Pages (from-to)1005-1013
Number of pages9
JournalPharmacoEconomics
Volume36
Issue number8
DOIs
StatePublished - Aug 1 2018

Fingerprint

Neuroendocrine Tumors
Patient Care
Costs and Cost Analysis
Neoplasms
Cost of Illness
Terminal Care
Medicare
Human Body
Health Care Costs
Pancreas
Epidemiology
Economics
Control Groups
Survival
Incidence

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Health Policy
  • Public Health, Environmental and Occupational Health

Cite this

Shen, Chan ; Dasari, Arvind ; Gu, Dian ; Chu, Yiyi ; Zhou, Shouhao ; Xu, Ying ; Halperin, Daniel ; Fu, Shuangshuang ; Yao, James C. ; Shih, Ya Chen Tina. / Costs of Cancer Care for Elderly Patients with Neuroendocrine Tumors. In: PharmacoEconomics. 2018 ; Vol. 36, No. 8. pp. 1005-1013.
@article{87765b61998f4f03b8a4081f17bbd823,
title = "Costs of Cancer Care for Elderly Patients with Neuroendocrine Tumors",
abstract = "Background: The incidence and prevalence of neuroendocrine tumors (NETs) have been steadily rising. NETs can arise in various parts of the body and have distinct pathogenesis, clinical manifestations, treatment, and survival compared to other neoplasms. The magnitude of the economic burden of NETs is largely unknown. This study aimed to estimate the cost of illness for NETs among elderly patients based on a large amount of observational data. Methods: We estimated the direct medical costs by phase of care using the Surveillance, Epidemiology, and End Results-Medicare data, including claims from January 1, 2002 through to December 31, 2012. Patients’ care was categorized into three phases: initial phase (first year after diagnosis), terminal phase (last year of life), and continuing phase (the period between). We estimated the cost of illness by calculating the difference in medical costs between NET patients and a matched sample from a non-cancer control group. Results: Our study sample included 8409 elderly NET patients in the initial phase, 9218 patients in the continuing phase, and 7897 in the terminal phase. The mean cost of care for the initial phase was $46,462 in 2016 US dollars; mean cost of care for the terminal phase with a cancer-related death was $122,702; while the mean cost of care for the continuing phase was $10,457. The mean 5-year cost was $87,079. Conclusions: This population-based study showed that NET patients had substantial continuing phase costs and 5-year costs. Among elderly NET patients, those with pancreas as the primary cancer site had the highest costs.",
author = "Chan Shen and Arvind Dasari and Dian Gu and Yiyi Chu and Shouhao Zhou and Ying Xu and Daniel Halperin and Shuangshuang Fu and Yao, {James C.} and Shih, {Ya Chen Tina}",
year = "2018",
month = "8",
day = "1",
doi = "10.1007/s40273-018-0656-z",
language = "English (US)",
volume = "36",
pages = "1005--1013",
journal = "PharmacoEconomics",
issn = "1170-7690",
publisher = "Adis International Ltd",
number = "8",

}

Shen, C, Dasari, A, Gu, D, Chu, Y, Zhou, S, Xu, Y, Halperin, D, Fu, S, Yao, JC & Shih, YCT 2018, 'Costs of Cancer Care for Elderly Patients with Neuroendocrine Tumors', PharmacoEconomics, vol. 36, no. 8, pp. 1005-1013. https://doi.org/10.1007/s40273-018-0656-z

Costs of Cancer Care for Elderly Patients with Neuroendocrine Tumors. / Shen, Chan; Dasari, Arvind; Gu, Dian; Chu, Yiyi; Zhou, Shouhao; Xu, Ying; Halperin, Daniel; Fu, Shuangshuang; Yao, James C.; Shih, Ya Chen Tina.

In: PharmacoEconomics, Vol. 36, No. 8, 01.08.2018, p. 1005-1013.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Costs of Cancer Care for Elderly Patients with Neuroendocrine Tumors

AU - Shen, Chan

AU - Dasari, Arvind

AU - Gu, Dian

AU - Chu, Yiyi

AU - Zhou, Shouhao

AU - Xu, Ying

AU - Halperin, Daniel

AU - Fu, Shuangshuang

AU - Yao, James C.

AU - Shih, Ya Chen Tina

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Background: The incidence and prevalence of neuroendocrine tumors (NETs) have been steadily rising. NETs can arise in various parts of the body and have distinct pathogenesis, clinical manifestations, treatment, and survival compared to other neoplasms. The magnitude of the economic burden of NETs is largely unknown. This study aimed to estimate the cost of illness for NETs among elderly patients based on a large amount of observational data. Methods: We estimated the direct medical costs by phase of care using the Surveillance, Epidemiology, and End Results-Medicare data, including claims from January 1, 2002 through to December 31, 2012. Patients’ care was categorized into three phases: initial phase (first year after diagnosis), terminal phase (last year of life), and continuing phase (the period between). We estimated the cost of illness by calculating the difference in medical costs between NET patients and a matched sample from a non-cancer control group. Results: Our study sample included 8409 elderly NET patients in the initial phase, 9218 patients in the continuing phase, and 7897 in the terminal phase. The mean cost of care for the initial phase was $46,462 in 2016 US dollars; mean cost of care for the terminal phase with a cancer-related death was $122,702; while the mean cost of care for the continuing phase was $10,457. The mean 5-year cost was $87,079. Conclusions: This population-based study showed that NET patients had substantial continuing phase costs and 5-year costs. Among elderly NET patients, those with pancreas as the primary cancer site had the highest costs.

AB - Background: The incidence and prevalence of neuroendocrine tumors (NETs) have been steadily rising. NETs can arise in various parts of the body and have distinct pathogenesis, clinical manifestations, treatment, and survival compared to other neoplasms. The magnitude of the economic burden of NETs is largely unknown. This study aimed to estimate the cost of illness for NETs among elderly patients based on a large amount of observational data. Methods: We estimated the direct medical costs by phase of care using the Surveillance, Epidemiology, and End Results-Medicare data, including claims from January 1, 2002 through to December 31, 2012. Patients’ care was categorized into three phases: initial phase (first year after diagnosis), terminal phase (last year of life), and continuing phase (the period between). We estimated the cost of illness by calculating the difference in medical costs between NET patients and a matched sample from a non-cancer control group. Results: Our study sample included 8409 elderly NET patients in the initial phase, 9218 patients in the continuing phase, and 7897 in the terminal phase. The mean cost of care for the initial phase was $46,462 in 2016 US dollars; mean cost of care for the terminal phase with a cancer-related death was $122,702; while the mean cost of care for the continuing phase was $10,457. The mean 5-year cost was $87,079. Conclusions: This population-based study showed that NET patients had substantial continuing phase costs and 5-year costs. Among elderly NET patients, those with pancreas as the primary cancer site had the highest costs.

UR - http://www.scopus.com/inward/record.url?scp=85045734132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045734132&partnerID=8YFLogxK

U2 - 10.1007/s40273-018-0656-z

DO - 10.1007/s40273-018-0656-z

M3 - Article

VL - 36

SP - 1005

EP - 1013

JO - PharmacoEconomics

JF - PharmacoEconomics

SN - 1170-7690

IS - 8

ER -